EISAI CO., LTD. et al v. AUROBINDO PHARMA LTD. et al
| EISAI CO., LTD., EISAI INC. and NOVARTIS PHARMA AG |
| AUROBINDO PHARMA LTD. and AUROBINDO PHARMA USA, INC. |
| 1:2022cv03610 |
| June 8, 2022 |
| US District Court for the District of New Jersey |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on June 8, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 3 Corporate Disclosure Statement by NOVARTIS PHARMA AG. (DENI, WILLIAM) |
| Filing 2 Corporate Disclosure Statement by EISAI CO., LTD., EISAI INC.. (DENI, WILLIAM) |
| Filing 1 COMPLAINT against AUROBINDO PHARMA LTD., AUROBINDO PHARMA USA, INC. ( Filing and Admin fee $ 402 receipt number ANJDC-13472715) , Related Case Selected, filed by EISAI CO., LTD., NOVARTIS PHARMA AG, EISAI INC.. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet, #3 L. Civ. R. 11.2 & 40.1 Certification)(DENI, WILLIAM) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the New Jersey District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
